BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced that the U.S. Food and Drug Administration (FDA) has a...
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-m...
-Galux, a South Korean biotech pioneering AI-driven protein therapeutics design, announced new experimental findings demonstrating that its AI protein de...
Aidoc, the global leader in clinical AI with the most FDA-cleared CAD solutions, announced a major milestone: the completion of its pivotal study a...
-Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, announced the U....
MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills ...
Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partners...
Data reveals positive preliminary results for investigational agent tinostamustine as a potential first-in-class treatment for glioblastoma. -...
Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allows flex...
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced that it has completed the acquisit...
First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytoki...
Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint bl...
Thermo Fisher Scientific Inc., the world leader in serving science, announced the enrollment of the first patient in the new PPD™ CorEvitas&t...
Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic ca...
© 2025 Biopharma Boardroom. All Rights Reserved.
